Journal
FUTURE ONCOLOGY
Volume 9, Issue 12, Pages 1871-1881Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FON.13.140
Keywords
adjuvant chemotherapy; biological age; breast cancer; comprehensive geriatric assessment; elderly; frailty screening
Categories
Funding
- Sandro Pitigliani Foundation
Ask authors/readers for more resources
Management of older breast cancer patients is challenging due to a lack of good quality evidence regarding the role of adjuvant chemotherapy. Older women can benefit as much from adjuvant chemotherapy as younger women, although they have an increased risk of toxicities. Decisions regarding adjuvant chemotherapy should be made based on tumor biology and biological age, rather than chronological age. Geriatrician assessment can detect subtle functional deficits that may impact on the ability of the patient to tolerate chemotherapy; however, implementation of comprehensive geriatric assessment in the oncology setting is challenging. Instead, numerous frailty screening tools are in development. Future advances should incorporate more accurate and efficient means for determining the biological age of elderly breast cancer patients, which will better define the risk: benefit ratio of adjuvant chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available